Literature DB >> 7923210

Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma.

M Shiseki1, T Kohno, R Nishikawa, Y Sameshima, H Mizoguchi, J Yokota.   

Abstract

Although it is widely accepted that tumor suppressor genes play an important role in the genesis and progression of human cancer, little is known about genetic events that accumulate during multistage lung carcinogenesis. Thus, to determine a subset of tumor suppressor genes that are involved in the genesis and progression of non-small cell lung carcinoma (NSCLC), 22 brain metastases and 23 stage I primary lung tumors were examined for allelic losses at 40 loci on 10 chromosomes including the loci of 5 tumor suppressor genes, APC, WT1, RB, p53, and DCC. The incidence of allelic losses on chromosomes 3p, 13q, and 17p was high (> 60%) in both primary tumors and brain metastases. In brain metastases, a high incidence of allelic losses (> 60%) was also observed at loci on chromosomes 2q, 18q, and 22q, and the incidence of allelic losses on these chromosomes in brain metastases was significantly higher than that in primary tumors (P < 0.05). In two cases of brain metastases with corresponding primary lung tumors, sequential accumulation of allelic losses during progression of primary lung tumors was observed on several chromosomes including chromosomes 2q and 18q. These results indicate that, besides loss of heterozygosity for chromosomes 3p, 13q, and 17p, loss of heterozygosity for chromosomes 2q, 18q, and 22q also occurs frequently in advanced NSCLCS. Thus, it is possible that loss of heterozygosity on chromosomes 2q, 18q, and 22q occurs late in the progression of NSCLC and/or causes phenotypic alterations of NSCLC cells into more aggressive ones.

Entities:  

Mesh:

Year:  1994        PMID: 7923210

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Lipoprotein receptors--an evolutionarily ancient multifunctional receptor family.

Authors:  Marco Dieckmann; Martin Frederik Dietrich; Joachim Herz
Journal:  Biol Chem       Date:  2010-11       Impact factor: 3.915

2.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 3.  Molecular determinants of lung cancer metastasis to the central nervous system.

Authors:  Timothy G Whitsett; Landon J Inge; Harshil D Dhruv; Philip Y Cheung; Glen J Weiss; Ross M Bremner; Jeffrey A Winkles; Nhan L Tran
Journal:  Transl Lung Cancer Res       Date:  2013-08

4.  Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung.

Authors:  K Takamochi; T Ogura; K Suzuki; H Kawasaki; Y Kurashima; T Yokose; A Ochiai; K Nagai; Y Nishiwaki; H Esumi
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Allelic loss on 17p13 (TP53) and allelic loss on 3p21 in early squamous cell carcinoma of the lung.

Authors:  C Endo; M Sato; S Fujimura; A Sakurada; H Aikawa; S Takahashi; K Usuda; Y Saito; M Sagawa
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

6.  Topographical distributions of allelic loss in individual non-small-cell lung cancers.

Authors:  Y Yatabe; H Konishi; T Mitsudomi; S Nakamura; T Takahashi
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

7.  Mutation and expression of the DCC gene in human lung cancer.

Authors:  T Kohno; T Sato; S Takakura; K Takei; K Inoue; M Nishioka; J Yokota
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

8.  MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer.

Authors:  Michiho Nishioka; Takashi Kohno; Masachika Tani; Nozomu Yanaihara; Yoshio Tomizawa; Ayaka Otsuka; Shigeru Sasaki; Keiko Kobayashi; Toshiro Niki; Arafumi Maeshima; Yoshitaka Sekido; John D Minna; Saburo Sone; Jun Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

9.  Decreased expression of DCC mRNA in gastric and colorectal cancer.

Authors:  M Kataoka; T Okabayashi; K Orita
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

10.  Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.

Authors:  Gayane Badalian; Tamás Barbai; Erzsébet Rásó; Katalin Derecskei; Miklós Szendrôi; József Tímár
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.